Skip to main content
. Author manuscript; available in PMC: 2017 Nov 22.
Published in final edited form as: Oncogene. 2017 May 22;36(38):5421–5431. doi: 10.1038/onc.2017.143

Figure 3. Inhibition of PAK1/2/3 affects MAPK, Akt, β-catenin pathways and cadherin expression.

Figure 3

Immunoblot analysis of MAPK, AKT/mTOR and β-catenin cascades signaling and N- and E-cadherin protein levels changes in iHSC, ST8814, STS26T and S462TY cells exposed to PAK1/2/3 inhibitors GST-PID and Frax1036. WB quantification of Pak, Mek/Erk, Akt/mTOR phosphorylation changes and changes of active β-catenin levels Error bars represent standard deviation (*= p<0.05, **= p<0.01).